NSPR vs ATEC vs SYK vs ANGO

For growth investors, InspireMD, Inc.

(NSPR) is the stronger pick with 28. 1% revenue growth year-over-year, versus -3. 8% for AngioDynamics, Inc. (ANGO). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Alphatec Holdings, Inc. (ATEC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Stryker Corporation is actually cheaper at 19.

6x.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -77. 0% for InspireMD, Inc. (NSPR). Over 10 years, the gap is even starker: ATEC returned +225. 4% versus NSPR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 142% more volatile than SYK relative to the S&P 500. On balance sheet safety, InspireMD, Inc. (NSPR) carries a lower debt/equity ratio of 4% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), InspireMD, Inc.

(NSPR) is pulling ahead at 28. 1% versus -3. 8% for AngioDynamics, Inc. (ANGO). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to 0. 0% for InspireMD, Inc.. Over a 3-year CAGR, ATEC leads at 29. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -543. 3% for InspireMD, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -547. 0% for NSPR. At the gross margin level — before operating expenses — ATEC leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Stryker Corporation (SYK) trades at 19.

6x forward P/E versus 27. 1x for Alphatec Holdings, Inc. — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

In this comparison, SYK (1.

1% yield) pays a dividend. NSPR, ATEC, ANGO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NSPR is a small-cap high-growth stock; ATEC is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock; ANGO is a small-cap quality compounder stock. SYK pays a dividend while NSPR, ATEC, ANGO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.